Marcos Agramont reports
ISODIOL INTERNATIONAL INC. ANNOUNCES LAUNCH OF MARKET'S FIRST HOPS-DERIVED CBD PRODUCTS
Isodiol International Inc. has launched the market's first non-cannabis, highly bioactive cannabinoid (CBD) derived from the hops plant; a globally accepted plant. The cannabinoids are derived using proprietary genetics and extraction technology that allow for the isolation of the cannabinoids and terpenes without denaturing the molecule.
Hops-derived cannabinoid products have shown a favourable response and promising results in independent clinical studies for various diseases. Sourcing natural, highly bioactive cannabinoids to supplement the endocannabinoid system in the human body is key to developing targeted health care remedies.
"The development of the technology to extract cannabinoids from a plant other than cannabis without denaturing the molecule is an incredible achievement," said Marcos Agramont, chief executive officer of Isodiol International. "As the regulatory framework within the United States continues to mature, the establishment of a new non-cannabis source of CBD and the continued growth of our international pharmaceutical footprint will differentiate Isodiol as the global leader."
The company will continue to collaborate with universities and alternative health facilities in the United States and overseas to validate the science. It anticipates products will be ready for distribution within the next four weeks.
This announcement is on the heels of the company's introduction of its phytoceutical division on Sept. 5, 2017.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.